Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new treatment option for tough-to-treat breast cancer is going global. China's NMPA and Japan's MHLW have both approved datopotamab deruxtecan (Dato-DXd) for patients with metastatic triple-negative breast cancer (TNBC) who can't receive immunotherapy. The approvals are backed by phase 3 TROPION-Breast02 trial data showing Dato-DXd significantly extended survival compared to standard chemotherapy.
China's National Medical Products Administration (NMPA) and Japan's Ministry of Health, Labour and Welfare (MHLW) have both approved datopotamab deruxtecan (Dato-DXd; Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The decisions follow a similar FDA approval in May 2026, making Dato-DXd a newly established global standard of care for this population.
TNBC patients ineligible for immunotherapy have historically had very limited first-line options, making these approvals a meaningful step forward. Dato-DXd is a TROP2-directed antibody-drug conjugate — a precision therapy that delivers chemotherapy directly to cancer cells.
Why it matters: TNBC is one of the most aggressive and difficult-to-treat breast cancer subtypes, and patients who can't receive immunotherapy have faced a stark lack of effective options. With regulatory approvals now spanning the US, China, and Japan, Dato-DXd is poised to reshape first-line treatment for this underserved population worldwide.
